← Eichor
Condition: Idh1 Mutated Malignancies Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Idh1 Mutated Malignancies

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Phase 2 · 1 location(s) · Timothy Pardee · NCT07471841A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treat
Phase 3 · 114 location(s) · Servier Bio-Innovation LLC · NCT06127407ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
Phase N/A · 1 location(s) · CHA University · NCT07151118a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07007949A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid M
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06668584Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
Phase N/A · 1 location(s) · CHA University · NCT07142226Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Phase 1 · 2 location(s) · City of Hope Medical Center · NCT06543381Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Phase 3 · 53 location(s) · Hutchmed · NCT06387069A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) M
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05588141Ivosidenib as Post-HSCT Maintenance for AML
Phase 2 · 6 location(s) · Massachusetts General Hospital · NCT06707493Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Phase 1 · 30 location(s) · Institut de Recherches Internationales Servier · NCT02074839Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemi
Phase N/A · 13 location(s) · iOMEDICO AG · NCT06607302Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML
Phase 3 · 119 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT07075016Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M
Phase 2 · 12 location(s) · Technische Universität Dresden · NCT06717958Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
Phase 1 · 1 location(s) · University of Chicago · NCT06291987A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Phase 1 · 19 location(s) · Servier Bio-Innovation LLC · NCT07006688Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m
Phase 3 · 15 location(s) · Servier Affaires Médicales · NCT05907057Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Act
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07032727Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Phase 4 · 2 location(s) · Rigel Pharmaceuticals · NCT07486713Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07607418Diagnostic and Therapeutic Targets in Cartilaginous Tumours
Phase N/A · 1 location(s) · St. Anne's University Hospital Brno, Czech Republic · NCT07315542A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Phase 1 · 15 location(s) · Nuvectis Pharma, Inc. · NCT05873686Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I
Phase 2 · 1 location(s) · Justin Watts, MD · NCT06782542Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leuke
Phase 2 · 1 location(s) · University of California, Davis · NCT07304011Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/Phase 2 · 4 location(s) · M.D. Anderson Cancer Center · NCT03471260
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.